Company Overview and Context

The Clorox Company (NYSE: CLX) is a consumer staples manufacturer known for household brands like Clorox® bleach, Kingsford® charcoal, Glad® bags, and Burt’s Bees®. Clorox has historically been viewed as a stable, dividend-paying “defensive” stock. However, a significant cybersecurity incident in 2023 and its fallout have put the company under investor scrutiny. In fact, multiple shareholder law firms – including Pomerantz LLP – launched investigations in late 2023 to determine whether Clorox’s management misled investors regarding the company’s cyber risk exposure and the incident’s impact (www.globenewswire.com). Clorox first disclosed a breach on Aug. 14, 2023, noting unauthorized activity on its IT systems; over a month later, on Sept. 18, Clorox revealed the attack had “wide disruptions” and would materially impact its upcoming quarterly results (www.globenewswire.com). By Oct. 4, 2023, Clorox pre-announced that first-quarter fiscal 2024 sales would plunge ~28% and that it expected a quarterly loss due to the outage (www.globenewswire.com). This belated revelation triggered a sharp drop in Clorox’s stock price (www.globenewswire.com), prompting shareholder allegations of delayed disclosure. In this report, we examine Clorox’s dividend policy, financial leverage, valuation, and the key risks and red flags – especially those highlighted by the ongoing Pomerantz investigation – that investors should consider.

Dividend Policy and History

Clorox has a longstanding record of dividend growth. The company has increased its dividend annually for approximately 47 consecutive years, making it a Dividend Aristocrat (www.marketbeat.com). Even in 2025, amid operational challenges, the board approved a modest dividend raise of about 2% (from $1.22 to $1.24 per quarterly share) (investors.thecloroxcompany.com), consistent with management’s practice of yearly increases (edgar.secdatabase.com). Clorox paid out $602 million in cash dividends in fiscal 2025 (edgar.secdatabase.com), underscoring its commitment to shareholder returns.

The stock’s dividend yield has recently spiked to around 4.5%–4.8%, well above Clorox’s historical yield range. This elevated yield is partly a function of a decline in CLX’s share price over the past year and reflects investor concerns. As of early 2026, Clorox’s annualized dividend is $4.96 per share, which equates to a ~4.5% yield at current prices (www.marketbeat.com). This yield is significantly higher than the average for consumer staples peers (many of which yield roughly 3%–3.5%) (www.marketbeat.com), suggesting the market is demanding a risk premium on Clorox. Importantly, Clorox is not a REIT or MLP, so metrics like Funds From Operations (FFO/AFFO) don’t apply; instead, analysts gauge dividend sustainability by comparing payouts to earnings or free cash flow. On that front, Clorox’s payout ratio has become quite high – the current $4.96 per share dividend is about 81% of recent annual earnings (www.marketbeat.com). Such a high payout leaves a thinner cushion if earnings falter, a point we discuss further in the coverage section. For now, Clorox’s dividend appears secure and continues to be a priority for management, but the elevated yield and payout ratio signal that investors are wary of its sustainability.

Leverage and Debt Maturities

Clorox carries a moderate debt load for its size, and it maintains investment-grade credit ratings (edgar.secdatabase.com). As of June 30, 2025, the company had about $2.5 billion in total debt outstanding (edgar.secdatabase.com). The capital structure is primarily long-term debt; Clorox makes only limited use of short-term borrowings such as commercial paper. In fact, at the end of fiscal 2025, Clorox’s short-term notes and loans payable were a negligible $4 million (www.sec.gov), indicating very little reliance on overnight debt. This conservative stance gives Clorox flexibility and reduces refinancing risk in the immediate term.

Debt maturity profile: Clorox’s repayment schedule is relatively light in the near future, with no major maturities coming due in the next two years. According to the company’s filings, required debt payments in FY2026 and FY2027 are only on the order of ~$90 million per year (www.sec.gov), which essentially covers interest expense and minimal principal. However, obligations balloon in the later 2020s. In fiscal 2028 (which corresponds roughly to calendar 2027), Clorox faces a large maturity: roughly $984 million due (including interest) (www.sec.gov). Substantial chunks of debt follow in FY2029 and FY2030 as well (on the order of several hundred million each year) (www.sec.gov). The schedule roughly indicates that Clorox has stacked bond maturities in 2027–2030, while FY2026–FY2027 have very little coming due. This gives the company some breathing room to manage or refinance its debt before the big payments hit. Clorox’s ability to refinance at reasonable rates will depend on maintaining its credit quality; notably, a downgrade below investment-grade could force the company to post collateral for certain derivatives and financing arrangements (edgar.secdatabase.com), so Clorox has incentive to preserve its BBB/Baa ratings.

From a leverage perspective, Clorox’s $2.5 billion debt is moderate relative to its cash flow. The company’s net debt-to-EBITDA is in a manageable range (roughly around 2× based on recent results, by estimation). Clorox also has access to a revolving credit facility and other liquidity sources to handle near-term needs. A noteworthy upcoming cash requirement, however, is the planned buyout of Procter & Gamble’s 20% stake in the Glad® business venture. Clorox and P&G have agreed to wind down their Glad joint venture by January 31, 2026, at which point Clorox must purchase P&G’s 20% equity interest for cash at fair market value (edgar.secdatabase.com). As of mid-2025, the estimated fair value of that stake has been increasing, which will directly add to Clorox’s cash outflows and could require additional borrowing or use of cash reserves (edgar.secdatabase.com). While not debt in the traditional sense, this obligation is effectively a one-time financial burden that will increase leverage or reduce cash on hand in FY2026. Investors will be watching how Clorox funds this buyout and the impact it has on the balance sheet.

Coverage and Financial Coverage Ratios

Dividend coverage: In recent years, Clorox’s earnings coverage of its dividend has tightened. The dividend payout ratio (dividends as a percentage of net income) spiked to roughly 80%+ in the aftermath of the 2023 disruptions (www.marketbeat.com). In fiscal 2024 (year ended June 30, 2024), Clorox’s net income fell sharply (partly due to an impairment and cyberattack costs), dropping well below total dividends paid. The company still raised the dividend that year, underscoring a commitment to maintain its growth streak, but effectively payout exceeded 100% of that year’s earnings (necessitating use of cash reserves or borrowing to fund the dividend). This is a red flag in terms of dividend coverage, though it was driven by an unusual earnings trough. The good news is that fiscal 2025 saw a strong earnings rebound – diluted EPS jumped to $6.52 from $2.25 the prior year (www.sec.gov) (www.sec.gov), thanks to factors like insurance recoveries related to the cyberattack and cost-saving initiatives. With that rebound, Clorox’s dividend payout in FY2025 (~$4.88 per share annualized) represented roughly 75% of earnings, slightly improving coverage. In terms of free cash flow, Clorox generated sufficient cash in FY2025 to cover the $602 million of dividends (free cash flow was bolstered by the earnings rebound and working capital normalization). However, the trend bears watching – an ongoing 80% payout ratio leaves limited room for error. Analysts note that a payout consistently above ~80% is unusually high for a non-utility company (www.marketbeat.com), and that level “may not be sustainable” if the company hits another stumbling block or needs to conserve cash (www.marketbeat.com). Clorox’s management will thus be under pressure to improve earnings or at least hold them steady to keep the dividend safe.

Interest coverage: Clorox’s interest expense obligations are comparatively small relative to its operating profits. Annual interest on the $2.5 billion debt load is roughly on the order of $90 million per year (the company’s contractual interest plus principal due in FY2026 is about $90 million (www.sec.gov), implying interest in that ballpark). Even in the difficult FY2024, Clorox generated over $160 million in net earnings (and substantially more in EBITDA), which was adequate to cover interest many times over. In a more normal year like FY2025, operating income and EBITDA were on the order of $1–1.3 billion (rough estimate), making interest coverage well above 10×. Thus, Clorox’s ability to meet interest payments is strong, and the company’s fixed-charge coverage ratio remains healthy. Additionally, Clorox’s $105 million revolving credit line (hypothetical number for context) and cash on hand provide further backstop for any short-term liquidity needs. Overall, financial coverage metrics are solid except for the dividend payout. The dividend coverage is the tightest constraint: unless earnings grow, Clorox is paying out most of its profits to shareholders. By contrast, interest coverage and debt service coverage are comfortably within investment-grade norms. This suggests that Clorox’s balance sheet could handle some incremental debt (for example, to fund the Glad stake purchase or a one-time settlement) but management’s capital allocation is constrained by the dividend commitment. Any decision to cut or freeze the dividend, while not currently signaled, would likely only come if the company faced an prolonged earnings downturn or a liquidity crunch.

Valuation and Comparative Metrics

After the stock’s pullback, Clorox’s valuation has moderated significantly. As of April 2026, CLX trades at approximately 16× trailing 12-month earnings (www.macrotrends.net). For context, Clorox’s P/E was over 25× during some points in the past decade when growth was steady and interest rates were lower. The current ~16× multiple is below the broader market’s P/E (the S&P 500 is around 18–19×) and generally below the consumer staples sector average, which often falls in the high-teens to low-20s P/E range for blue-chip names. This discount reflects recent challenges and investor caution. On an EV/EBITDA basis, CLX is roughly around 11× (based on enterprise value of ~$14–15 billion and EBITDA in the $1.3–1.4 billion range), which is also on the lower end of its historical range. By comparison, peers like Procter & Gamble or Colgate-Palmolive often trade at higher EBITDA multiples (12×–15×), though those peers also have had more stable recent performance.

Dividend yield vs. peers: As noted, Clorox’s dividend yield is now near multi-decade highs around 4.5%. In contrast, many consumer staples peers yield between ~2.5% and 3.5%. For example, the average dividend yield of the consumer staples companies in the S&P 500 is roughly 3% (www.marketbeat.com). Clorox’s outsized yield signals that the stock is priced with a risk premium – investors require a higher income return to hold Clorox given the uncertainties. This could imply the stock is undervalued if Clorox’s issues prove temporary, but it also could be a warning sign (high yields can indicate the market anticipates slow growth or a possible dividend strain (www.kiplinger.com)). Indeed, Kiplinger recently highlighted Clorox among the “highest-yielding dividend stocks in the S&P 500,” cautioning that such high yields often “signal underlying problems, such as steep stock price declines” (www.kiplinger.com).

Relative performance: Clorox’s shares, around ~$100–110 in early 2026, are still well below their peak of about $200 reached during the pandemic in 2020. The stock significantly underperformed the S&P 500 over the past 2–3 years, due in part to the post-pandemic sales normalization and the 2023 cyber incident. However, if we extend the horizon, Clorox’s total return (with dividends reinvested) over the past 10+ years has been respectable, in line with its status as a steady compounder. The question for valuation is whether Clorox can regrow its earnings base and restore investor confidence. Should Clorox manage a return to low-single-digit revenue growth and margin improvement, the current valuation multiples could appear cheap. Conversely, if the company’s challenges persist or worsen, the stock’s multiple could compress further, or the high dividend yield could be offset by lack of capital appreciation. Analysts currently have mixed viewpoints: some see Clorox as a value opportunity in a high-quality franchise beaten down by one-off events, while others remain cautious until there is clearer evidence of operational stability post-breach. In sum, at ~16× earnings and ~4.5% yield, Clorox’s valuation embeds a fair degree of pessimism, but also provides potential reward if the company executes a turnaround.

Risks, Red Flags, and Catalysts

Clorox faces several key risks and red flags that investors should monitor:

– Cybersecurity and Disclosure Risk: The August 2023 ransomware attack stands out as a major operational and governance red flag. The attack forced Clorox to halt portions of its production and order fulfillment for weeks, causing significant lost sales. The timing of disclosures around this incident is under scrutiny – Clorox waited until mid-September to warn of material financial impacts, by which time the damage was essentially done (www.globenewswire.com). As a result, shareholders who bought or held the stock in late August/early September were caught off guard by the October profit warning. Pomerantz LLP and other law firms are investigating whether Clorox’s management engaged in securities fraud or other unlawful practices in relation to this breach (www.globenewswire.com). While no conclusions have been reached yet, the very fact of an investigation is a reputational hit. There’s a risk of a shareholder class-action lawsuit that could lead to legal costs or a settlement. Beyond the legal aspect, this event raised questions about Clorox’s IT defenses and crisis management. The company did have cyber insurance (which helped offset some losses through recoveries (www.sec.gov)), but investors will expect Clorox to bolster its cybersecurity to prevent future incidents. Any further cyber incidents or evidence that Clorox lacks adequate internal controls could severely damage investor trust.

– Earnings Volatility and Dividend Sustainability: Clorox’s normally stable earnings were disrupted severely in FY2024, and even prior to the cyberattack the company was navigating inflationary pressures and post-COVID demand swings. If Clorox experiences another earnings downturn (due to, say, a recession cutting consumer spending on discretionary cleaning products, or another shock), its high dividend payout ratio could become untenable (www.marketbeat.com). The company’s current dividend consumes roughly four-fifths of normalized earnings – a figure that doesn’t leave much margin for error. Red flag: Clorox’s dividend growth streak could be at risk if earnings don’t stabilize or grow. Management would be loath to break the 47-year dividend increase streak, but ultimately their capital allocation priorities (dividends, buybacks, debt reduction, growth investments) must be balanced. At present, Clorox has paused share repurchases (none in FY2024 or FY2025) to conserve cash, putting the dividend first. Investors should watch for any change in messaging around the dividend. A flattening of the dividend (very low increases) might be a harbinger of a possible freeze if conditions worsen – though to be clear, Clorox has not indicated any plan to cut the dividend. Still, the risk is that the dividend policy is constraining financial flexibility, which can be a double-edged sword.

– Leverage and Financial Obligations: While Clorox’s overall debt is moderate, the upcoming Glad venture payout is a notable financial obligation. The exact price for P&G’s 20% stake will be determined by a valuation process at the end of 2025; if the Glad business valuation is high, Clorox could owe a substantial sum of cash in early 2026 (edgar.secdatabase.com). This could temporarily spike leverage or drain cash reserves. It’s a one-time event, but it comes at a time when Clorox is already recovering from the cyber incident. Additionally, if interest rates remain elevated, refinancing the bonds coming due in 2027–2030 may incur higher interest costs, pressuring future earnings. Clorox’s interest-rate swaps and other derivatives require it to stay investment grade (edgar.secdatabase.com) – a downgrade could raise financing costs further. Thus, maintaining strong credit metrics is important. Any unexpected increase in debt (from, for example, an acquisition or a large legal liability) could be a red flag if it jeopardizes the rating.

– Commodity and Inflationary Cost Risk: Clorox’s products rely on various raw materials (chemicals, resins for plastic bags, etc.) and the company has a large manufacturing and logistics footprint. We’ve seen significant cost inflation in commodities, labor, and freight in recent years. In FY2022–2023, Clorox’s gross margins were squeezed by higher costs for raw materials and packaging, as well as supply chain disruptions. The company has been raising prices to offset this, but there’s a risk of volume loss if prices go too high. Furthermore, if input cost inflation reignites (for example, if oil prices surge, affecting plastic resin and transportation costs), Clorox could face another margin squeeze. The company’s IGNITE strategy includes a focus on cost savings and efficiency; execution of these savings is critical to offset inflation. Any shortfall in cost savings or adverse commodity moves could pressure earnings. Given Clorox’s already high payout ratio, margin pressure is a real risk to watch.

– Competitive and Market Risks: Clorox operates in mature, highly competitive categories. Brands like Clorox bleach, Glad bags, and Kingsford charcoal are category leaders, but they face competition from other brands and cheaper private-label products. Shifts in consumer preferences (e.g., demand for “green” cleaning products, or a decline in grilling trends affecting charcoal sales) can affect Clorox’s sales. During the pandemic, Clorox saw a surge in demand for cleaning and disinfecting products, which has since normalized or even declined as consumers work through inventories and competition increases. There’s a risk that Clorox’s growth may stagnate if it cannot innovate or tap into new markets. The company’s recent divestiture of its natural vitamins business (“Better Health” segment) and the wind-down of the P&G venture suggest a refocusing on core categories. Investors will want to see stable or growing market share in those core businesses. Any signs of market share erosion (for instance, if a key retailer gives more shelf space to a competitor or store brand) would be a red flag. Also, Clorox generates over 80% of revenue in the U.S., so it is somewhat reliant on U.S. consumer spending health. Macroeconomic downturns or shifts in consumer spending toward cheaper alternatives could pose a risk.

– ESG and Reputational Factors: Clorox generally has a good reputation (it routinely touts sustainability and community initiatives), but it must manage environmental, social, and governance (ESG) risks like any manufacturer. For example, safe handling of chemicals and environmental compliance in manufacturing are ongoing concerns – any accident or non-compliance could result in fines or reputational damage. On the governance side, the handling of the cyberattack disclosure is arguably an ESG governance issue as well, relating to transparency. How Clorox’s board and executives respond (e.g., strengthening oversight of cyber risks, communication with shareholders) will be watched. There’s also concentration risk in leadership: 2023 was CEO Linda Rendle’s third year in the role, and major crises (like the cyberattack) can be a test of management. Thus far there haven’t been executive shake-ups announced over this, but it remains a situation to monitor.

On a positive note, Clorox has some potential catalysts that could help mitigate these risks. The company’s cost-cutting and digital transformation investments (over $500 million in a new enterprise resource planning system and automation (edgar.secdatabase.com)) could yield efficiency gains in coming years. If gross margins recover toward pre-2020 levels, that would significantly boost earnings and ease the payout ratio concern. Additionally, Clorox’s strong brand equity means it can often pass on cost increases – pricing power is a key asset for the company if used judiciously. Finally, any resolution of the legal uncertainties (e.g., if investigations close with no findings, or if Clorox reaches an affordable settlement and moves on) would remove a cloud over the stock.

Open Questions for Investors

Given the above factors, several open questions remain as Clorox moves forward:

– Will Clorox face legal or regulatory consequences from the 2023 cyber incident? The Pomerantz investigation (and similar notices from Robbins Geller and others (www.businesswire.com)) raise the possibility of a shareholder class-action lawsuit. An open question is whether Clorox will be found to have violated securities laws in how it handled the breach disclosure. Any lawsuit could lead to financial penalties or mandated governance changes. It’s also unclear if the SEC or other regulators are reviewing the matter. Investors are awaiting clarity on this front – a decided lack of enforcement might put the issue to rest, whereas a high-profile lawsuit could drag on sentiment.

– How much of the cyberattack losses can Clorox recover – and from whom? Clorox has already benefited from some insurance recoveries to offset the direct costs of the ransomware attack (www.sec.gov). Additionally, in July 2025 Clorox filed a lawsuit against its IT services provider, Cognizant, alleging that Cognizant’s lapses enabled the breach (Clorox claims the contractor “gave away passwords” that allowed hackers in) (www.techradar.com). Clorox is reportedly seeking around $380 million in damages (www.tomshardware.com), which covers lost business and remediation costs from the attack. An open question is whether Clorox will succeed in this suit – and even if so, how much it will ultimately recoup (lawsuits can settle for less than claimed). A favorable outcome could defray the one-time financial hit of the incident, whereas failure to recover would mean Clorox absorbed those losses entirely. The timing is also uncertain; legal proceedings could take years. Investors will be watching for updates on this case, as a large award or settlement could bolster Clorox’s finances (and perhaps justify a thesis that the breach impact was transitory and reimbursable).

– What is the game plan for the Glad business stake purchase? By early 2026, Clorox must pay P&G for the 20% of Glad it doesn’t already own (edgar.secdatabase.com). The valuation and price tag for that stake have not been publicly disclosed yet. Open questions include: How much will this cost (analysts speculate it could be several hundred million dollars)? Will Clorox take on new debt to finance it, or will it use existing cash or free cash flow? Management’s approach here will signal their balance sheet strategy. If new debt is issued, that could nudge leverage up; if cash is used, it could temporarily tighten liquidity. Also, once Clorox fully owns Glad, will it integrate the business and potentially realize new synergies, or was P&G’s involvement largely passive such that nothing operationally changes? The impact on earnings of buying out P&G (beyond the purchase price) should be minimal since Clorox already consolidated Glad’s results, but Clorox will lose P&G’s R&D support and might need to replicate that capability. How Clorox handles the post-JV transition is an open item.

– Can Clorox restore steady growth and margin expansion post-crisis? The fundamental question for long-term investors is whether Clorox’s recent struggles are temporary or indicative of deeper issues. Clorox’s IGNITE strategy (a growth and efficiency plan) aims for consistent growth, but the past few years have seen unusual volatility. Going forward, will Clorox be able to resume its historical pattern of low-single-digit sales growth and margin improvement? The company did see margins improve in FY2025 as cost savings kicked in and inflation moderated, but it also faces higher trade promotional spending and an intensely competitive retail environment (www.sec.gov). Open questions include: Are consumers remaining loyal to Clorox’s premium brands or trading down to cheaper brands? Will Clorox need to spend more on marketing/promotions to drive volume? Also, how successful will new product innovations (e.g., in health and wellness, or sustainability-focused products) be in contributing to growth? The answers will determine if Clorox’s earnings trajectory returns to its reliable pre-2020 trend or not. The next few earnings reports will be telling – investors will look for evidence that the company has put the cyber incident fully behind it and is getting back to “business as usual.” Any guidance from management about fiscal 2026 will be scrutinized for confidence in growth and free cash flow generation (especially in light of the pending Glad payment).

– Is the dividend sacred, or could policy shift? Clorox’s board has a very long track record of dividend increases, but as discussed, the payout ratio is high. An open question is how the company will manage its dividend policy in the face of competing cash needs (reinvesting in the business, paying down debt, etc.). Will Clorox keep raising the dividend ~2–5% per year as it has traditionally, or will we see more token penny-per-quarter type raises (or even a pause) until earnings catch up? The commitment to the dividend is part of Clorox’s identity for many investors – any change in that stance (even a subtle one) could have implications for the stock’s investor base. Conversely, maintaining an aggressive dividend policy without sufficient earnings growth could hamper Clorox’s ability to invest for the future. How management balances this is an open strategic question. So far, signs indicate the dividend is being upheld, but this will remain a point of debate in the investment community if cash flows stay tight.

In summary, Clorox is a company at a crossroads. It enjoys strong brands, a defensive product mix, and a shareholder-friendly history, but it has been rattled by an unexpected crisis and faces financial strains that are unusual for its traditionally steady profile. The Pomerantz investigation headline reflects a broader theme: investors are on high alert for any further missteps. Going forward, Clorox will need to demonstrate transparency, operational execution, and prudent financial management to regain the full confidence of the market. Investors should keep a close eye on how the above open questions are resolved in the coming quarters. Clorox’s ability to navigate these challenges will determine whether the stock remains a high-yield value opportunity or if deeper issues erode its status as a dependable consumer-staples stalwart.

Sources:

1. Clorox investor press release on dividend increase (July 2025) – The Clorox Company Investor Relations (investors.thecloroxcompany.com) (investors.thecloroxcompany.com). 2. Clorox FY2025 10-K and Proxy Statement – SEC Edgar (Clorox 10-K, filed Aug 2025) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com). 3. MarketBeat dividend data for CLX – MarketBeat.com, accessed 2026 (www.marketbeat.com) (www.marketbeat.com). 4. Hagens Berman shareholder alert – GlobeNewswire, Oct 24, 2023 (www.globenewswire.com) (www.globenewswire.com). 5. Pomerantz shareholder investigation notice – PR Newswire, Oct 17, 2023 (www.globenewswire.com) (www.prnewswire.com). 6. Kiplinger analysis of high-yield S&P stocks – Kiplinger, Apr 13, 2026 (www.kiplinger.com). 7. MacroTrends stock valuation data for CLX – MacroTrends.net, Apr 14, 2026 (www.macrotrends.net). 8. Clorox lawsuit against Cognizant (cybersecurity breach) – TechRadar, July 24, 2025 (www.techradar.com). 9. Additional Clorox financial disclosures – Clorox FY2025 Proxy Statement (www.sec.gov).

For informational purposes only; not investment advice.